Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

Award Number: R01CA286443
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2024
PERIOD OF PERFORMANCE END DATE: 07/31/2029

Group Awards By:

View Award Description

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer - Abstract Prostate cancer (PC) is one of the leading cause of cancer deaths among American men. Advanced PC patients often receive androgen deprivation therapy, but, the recalcitrant disease recurs within 2-3 years, referred to as the Castration Resistant Prostate Cancer (CRPC). Androgen Receptor (AR) antagonists such as enzalutamide (Enz) or abiraterone (Abi) are currently favored therapeutics for PC patients, however, virtually all patients develop resistance. Post-CRPC state, therapeutic options for the recurrent disease are limited. We discovered a non-receptor tyrosine kinase, ACK1, as a novel epigenetic modifier in prostate tumors, regulating AR/AR-V7 expression. Enthused with these data, we developed a new class of ACK1 small molecule kinase inhibitor, (R)-9b. (R)-9b inhibits ACK1 and downregulates AR and prostate specific antigen (PSA) expression to suppress prostate xenograft tumor growth. Moreover, in immune competent mouse models, (R)-9b induces significant CD4+ and CD8+ T cell activation against syngeneic prostate tumors. Employing ex vivo 3-D assays, we confirmed that (R)-9b functionally reinvigorates peripheral blood mononuclear cells (PBMCs) of the CRPC patients to mount a robust immune response against human CRPC organoids. Together, these data indicated that ACK1 inhibitor, (R)-9b with tumor-intrinsic and tumor-extrinsic activities in the host tumor microenvironments is a novel class of inhibitor with much needed immunomodulatory activity. Prolonged (R)-9b treatment exhibited normal histology suggesting that it is not associated with toxicity, further underscoring the importance of targeting ACK1 to overcome resistance to AR-targeted therapies. We have completed an extensive pre-Investigational New Drug (IND) studies including pharmacokinetic, pharmacodynamic and metabolism studies in mouse/rat/canine models, which revealed that (R)-9b possessed excellent drug-like properties. These data is submitted to FDA (IND#167907). This proposal is directed towards phase I clinical trial for ACK1 inhibitor (R)-9b in CRPC patients to examine its ability to overcome CRPC resistance by cytotoxic and immunomodulatory activity. Specifically, we will: Specific Aim 1: To assess the safety/tolerability, pharmacokinetics, and anti-tumor activity of (R)-9b in CPRC patients Specific Aim 2: To evaluate peripheral blood and tissue markers of anti-tumor and immune response after (R)-9b exposure. Overall, successful completion of this study will open a new therapeutic modality for CRPC patients who have developed resistance for Enzalutamide and Abiraterone, which is a critical unmet need.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $643,764 )
2025	2025	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Treatment Research	001	2	7/4/2025	NON-COMPETING CONTINUATION	$643,764
2025	2024	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Treatment Research	000	1	6/16/2025	NEW	$0
														Subtotal = $643,764

Issue Date FY: 2024 ( Subtotal = $652,414 )
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Treatment Research	000	1	8/9/2024	NEW	$652,414
														Subtotal = $652,414

Grand Total All Awards = $1,296,178

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

Award Number: R01CA286443

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2024

PERIOD OF PERFORMANCE END DATE: 07/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer